Back I am newly diagnosed Not yet treated

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

NCT03180307

III

Newly diagnosed stage III ovarian cancer

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

AZ, CA, FL, MI, MN, MO, PA

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
OTL38	fluorescent imaging ligand OTL38	Folate receptor imaging agent	Clinical Trials

NCT03602859

III

Newly diagnosed stage III/IV non-mucinous ovarian cancer (neo-adjuvant or adjuvant and maintenance)

ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

AK, CA, CT, FL, IL, LA, ME, MD, MA, MN, MT, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, UT, VA, WA

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Dostarlimab	ANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042	Blocks PD-L1/2 inhibition of T cells	Clinical Trials
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT03737643

III

Newly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant or adjuvant and maintenance)

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

CA, FL, GA, IL, IN, MD, MI, MO, NJ, NM, NY, NC, OH, OK, PA, UT

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT04095364

III

Newly diagnosed stage II-IV low grade serous ovarian cancer

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

AK, AR, CA, CO, DC, GA, ID, IL, IN, IA, KY, ME, MD, MN, MO, MT, NE, NV, NY, ND, OH, OK, OR, PA, RI, SD, TN, TX, VA, WA, WI, WY

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT02122185

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)

A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer

AL, CA, IL, MN

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Metformin	Fortamet, Glucophage, Glumetza, Riomet	AMP-activated protein kinase (AMPK) activator	Approved in Other Indications
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT02437812

Newly diagnosed stage II-IV ovarian cancer

A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Metformin	Fortamet, Glucophage, Glumetza, Riomet	AMP-activated protein kinase (AMPK) activator	Approved in Other Indications
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT02520154

Newly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant)

Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

NCT02834975

Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)

Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

NCT02766582

Newly diagnosed stage III/IV ovarian cancer after suboptimal debulking surgery

Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

NCT02033616

Newly diagnosed stage III/IV ovarian cancer

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

CA, CO

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AVOVA-1	TAA-loaded autologous dendritic cell vaccine, Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens	Anti-tumor immune response	Clinical Trials

NCT03531645

Newly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)

A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Fulvestrant	Faslodex, ICI 182,780, ZD9238	ER antagonist (SERD)	Approved in Other Cancers

NCT03993379

Advanced solid tumors

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

CA, ID, IL, KY, OR, VA, WA

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
CX-072	protease-activated anti-PD-L1 antibody prodrug CX-072	Blocks PD-L1 inhibition of T cells	Clinical Trials

NCT04082572

Advanced solid tumors with loss of MLH1, PMS2, MSH2 or MSH6 or with high MSI

Neoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid Cancers

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

NCT03206645

Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)

Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
PTC596	BMI1 inhibitor PTC596, polycomb ring finger oncogene inhibitor PTC596	BMI1 inhibitor	Clinical Trials

NCT03206177

Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma

Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Galunisertib	LY2157299	TGFBR1 antagonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT02713386

I/II

Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)

A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

AZ, CA, CT, DE, FL, GA, IL, IN, IA, KY, LA, MD, MA, MI, MN, MO, NE, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WV, WI

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Ruxolitinib	oral JAK inhibitor INCB18424, oral Janus-associated kinase inhibitor INCB18424, Jakafi, INCB18424	JAK1/2 kinase inhibitor	Approved in Other Indications

NCT02726997

I/II

Newly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant)

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT03394885

I/II

Newly diagnosed stage III-IV ovarian cancer (neo-adjuvant)

Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer

NC, VA

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT03393884

I/II

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

AL, CA, FL, MA, MO, MT, NJ, NY, OK, PA, RI, SD, TN, WI

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
GEN-1	PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPC	IL-12 receptor agonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT02933073

Newly diagnosed stage III/IV ovarian cancer or platinum sensitive ovarian cancer at first recurrence

A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
OncoImmunome		Anti-tumor immune response	Clinical Trials

NCT03054909

Stage III/IV ovarian cancer with stable disease or better after first-line IV/IP cisplatin and paclitaxel therapy (maintenance)

QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ALT-803		Activates NK cells to stimulate immune response	Clinical Trials

NCT03607955

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)

Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

MO, OK

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AVB-S6-500	AVB500	GAS6 antagonist	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

NCT03839524

High grade serous ovarian cancer with complete response after first-line platinum therapy (w/ banked tumor tissue)

A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.

AZ, FL, MN

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TG4050	Modified Vaccinia Ankara (MVA) personlized vaccine, MyVAC	Immune response against tumor-associated antigens	Clinical Trials

NCT04024878

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence)

NeoVax With Nivolumab in Patients With Ovarian Cancer

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NeoVax		Immune response against tumor-associated antigens	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

NCT04088786

Patients with peritoneal disease who are candidates for grossly complete cytoreduction surgery

Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies

CA, KY, NY

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Liposomal irinotecan	Onivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecan	Topoisomerase I inhibitor

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.